WO1997009973A3 - Peripherally active anti-hyperalgesic opiates - Google Patents

Peripherally active anti-hyperalgesic opiates Download PDF

Info

Publication number
WO1997009973A3
WO1997009973A3 PCT/US1996/014727 US9614727W WO9709973A3 WO 1997009973 A3 WO1997009973 A3 WO 1997009973A3 US 9614727 W US9614727 W US 9614727W WO 9709973 A3 WO9709973 A3 WO 9709973A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
active anti
methods
hyperalgesia
peripheral
Prior art date
Application number
PCT/US1996/014727
Other languages
French (fr)
Other versions
WO1997009973A2 (en
Inventor
Tony L Yaksh
John J Farrar
Alan L Maycock
Michael E Lewis
Gordon J Dow
Original Assignee
Univ California
Adolor Corp
Tony L Yaksh
John J Farrar
Alan L Maycock
Michael E Lewis
Gordon J Dow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Adolor Corp, Tony L Yaksh, John J Farrar, Alan L Maycock, Michael E Lewis, Gordon J Dow filed Critical Univ California
Priority to CA002229814A priority Critical patent/CA2229814C/en
Priority to BR9610345A priority patent/BR9610345A/en
Priority to JP51213697A priority patent/JP3553083B2/en
Priority to AU70710/96A priority patent/AU727982C/en
Priority to EP96931567A priority patent/EP0852494A2/en
Publication of WO1997009973A2 publication Critical patent/WO1997009973A2/en
Publication of WO1997009973A3 publication Critical patent/WO1997009973A3/en
Priority to NO980700A priority patent/NO980700L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and methods using the compositions for treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit substantial central nervous system effects. The anti-diarrheal compound 4-(p-chlorophenyl)-4-hydroxy-N-N-dimethyl-α,α-diphenyl-1-piperidinebutyramide hydrochloride is preferred for use in the compositions and methods.
PCT/US1996/014727 1995-09-12 1996-09-12 Peripherally active anti-hyperalgesic opiates WO1997009973A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002229814A CA2229814C (en) 1995-09-12 1996-09-12 Peripherally active anti-hyperalgesic opiates
BR9610345A BR9610345A (en) 1995-09-12 1996-09-12 Peripherally active antihyperalgesic opiates
JP51213697A JP3553083B2 (en) 1995-09-12 1996-09-12 Peripherally active antihyperalgesic opiates
AU70710/96A AU727982C (en) 1995-09-12 1996-09-12 Peripherally active anti-hyperalgesic opiates
EP96931567A EP0852494A2 (en) 1995-09-12 1996-09-12 Peripherally active anti-hyperalgesic opiates
NO980700A NO980700L (en) 1995-09-12 1998-02-19 Peripherally active anti-hyperalgesia opiates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US528,510 1995-09-12
US08/528,510 US5849761A (en) 1995-09-12 1995-09-12 Peripherally active anti-hyperalgesic opiates

Publications (2)

Publication Number Publication Date
WO1997009973A2 WO1997009973A2 (en) 1997-03-20
WO1997009973A3 true WO1997009973A3 (en) 1997-06-05

Family

ID=24105973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/014727 WO1997009973A2 (en) 1995-09-12 1996-09-12 Peripherally active anti-hyperalgesic opiates

Country Status (9)

Country Link
US (4) US5849761A (en)
EP (1) EP0852494A2 (en)
JP (2) JP3553083B2 (en)
KR (1) KR19990044182A (en)
AU (1) AU727982C (en)
BR (1) BR9610345A (en)
CA (2) CA2356097A1 (en)
NO (1) NO980700L (en)
WO (1) WO1997009973A2 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
RU2106864C1 (en) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров New approach to treatment of alzheimer's disease
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
WO1999024471A1 (en) * 1997-11-10 1999-05-20 The Research Foundation Of State University Of New York Opiate, cannabinoid, and estrogen receptors
GB9802542D0 (en) * 1998-02-05 1998-04-01 Smithkline Beecham Plc New use
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
AU4572999A (en) 1998-06-18 2000-01-05 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
AU758448B2 (en) * 1998-07-16 2003-03-20 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an NMDA antagonist
US6328765B1 (en) * 1998-12-03 2001-12-11 Gore Enterprise Holdings, Inc. Methods and articles for regenerating living tissue
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
SE9900961D0 (en) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6187822B1 (en) * 1999-06-11 2001-02-13 University Of Medicine & Dentistry Of Nj Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
US6696078B1 (en) * 1999-07-21 2004-02-24 Edwin J. Masters System and methods for local intradermal treatment
WO2001013938A1 (en) * 1999-08-25 2001-03-01 Daiichi Fine Chemical Co., Ltd. Medicinal composition for percutaneous/permucosal absorption
US6309662B1 (en) * 1999-09-23 2001-10-30 Janet Buchanan Use of anti-inflammatory drugs for treatment of dermatological conditions
CA2324330A1 (en) 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US7115664B2 (en) 2000-03-16 2006-10-03 Sepracor Inc. Peptidomimetic ligands for cellular receptors and ion channels
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
EP1325912A4 (en) * 2000-10-12 2004-05-12 Ssp Co Ltd 2,2-diphenylbutanamide derivatives and medicines containing the same
KR20010103057A (en) * 2001-01-31 2001-11-23 우원홍 Composition of miconazole for external application and skin-whitening
EP1385571B1 (en) * 2001-04-04 2008-07-30 Alza Corporation Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
WO2002089765A1 (en) * 2001-05-04 2002-11-14 Morepen Laboratories Ltd Method of preparing antibacterial gel and cotrimoxazole gel
DE50110158D1 (en) * 2001-09-06 2006-07-27 Friedrich Wolfgang Use of a mixture of lidocaine and prilocaine, and tumescent local anesthetic agents
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
WO2003052681A1 (en) * 2001-12-17 2003-06-26 International Barcode Corporation Double-sided bar code doubling as a single bar code
US20050131733A1 (en) * 2001-12-17 2005-06-16 Allen Lubow Sealable individual bar coded packets
MXPA04007832A (en) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aryl ureas with angiogenesis inhibiting activity.
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US6537590B1 (en) * 2002-02-19 2003-03-25 Troy J. Lee Solution and the method of making the same for the treatment of osteoarthritis
US20040122008A1 (en) * 2002-09-05 2004-06-24 Protter Andrew A. Treatment of pain by inhibition of p38 MAP kinase
CA2866848C (en) 2002-07-30 2017-01-03 Omeros Corporation Ophthalmologic irrigation solutions and method
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
DK1605956T3 (en) * 2002-12-18 2016-02-15 Ct Xion Therapeutics Corp ADMINISTRATION OF CAPSAICINOIDS TO TREAT OSTEOARTHRITIS
EP2491943B1 (en) 2003-02-04 2018-10-10 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
CA2524258C (en) 2003-05-01 2012-08-07 Cornell Research Foundation, Inc. Carrier complexes comprising cationic peptides for delivering molecules to cells
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
UA84156C2 (en) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
ITMI20031640A1 (en) * 2003-08-08 2005-02-09 Mipharm S P A BASE FOR BIOADHESIVE GEL.
CN1863522A (en) * 2003-10-06 2006-11-15 欧得士株式会社 Ophthalmic composition for treating lacrimal disorders
US20060047171A1 (en) * 2003-12-22 2006-03-02 Harold Meckler Catalytic hydrogenation of nitriles to produce capsaicinoid derivatives and amine compounds, and methods for purifying and obtaining the polymorphs thereof
US7622844B1 (en) * 2003-12-30 2009-11-24 Hipercon, Llc Metal fiber brush interface conditioning
JP4931604B2 (en) * 2004-01-23 2012-05-16 コーネル リサーチ ファウンデイション インコーポレイテッド Methods for reducing oxidative damage
BRPI0506548A (en) 2004-01-30 2007-05-02 Euro Celtique Sa Methods for Making 4-Tetrazolyl-4-Phenylpiperidine Compounds
US7454007B2 (en) * 2004-03-26 2008-11-18 Samsung Electronics Co., Ltd. Telecommunication switch using generic API to support multiple protocol-specific signal control functions
NZ550963A (en) * 2004-04-29 2008-11-28 Caldwell Galer Inc Topical methadone compositions and methods for using the same
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
JP2008515801A (en) 2004-10-01 2008-05-15 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク Morphine and morphine precursor
US20060115785A1 (en) 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
US7947508B2 (en) * 2004-11-30 2011-05-24 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US7766658B2 (en) 2004-11-30 2010-08-03 Align Technology, Inc. Systems and methods for intra-oral diagnosis
CN103948927B (en) * 2005-06-17 2017-11-07 威斯康星校友研究基金会 The topical vasoconstrictor preparations and method of cell are protected in cancer chemotherapy and radiotherapy
EP1749528A1 (en) 2005-08-05 2007-02-07 Pharma C S.A. Pharmaceutical combinations containing a mu opioid agonist and an inhibitor of NO production
WO2007025249A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
CA2947335A1 (en) 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
PT1928821E (en) 2005-09-21 2009-03-10 Pfizer Ltd Carboxamide derivatives as muscarinic receptor antagonists
NZ568430A (en) * 2005-11-21 2011-02-25 Purdue Pharma Lp 4-oxadiazolyl-piperidine compounds and use thereof
NZ575939A (en) 2006-11-01 2011-09-30 Purdue Pharma Lp Phenylpropionamide compounds and the use thereof
CA2713150C (en) 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
CN106975070A (en) 2008-02-26 2017-07-25 康奈尔大学 Method for preventing and treating acute injury of kidney
US8158682B2 (en) * 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8343912B2 (en) 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN103933542A (en) 2009-03-20 2014-07-23 通用医疗公司以马萨诸塞州通用医疗公司名义经营 Methods For The Prevention And Treatment Of Burn Injuries And Secondary Complications
JP5909182B2 (en) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー Methods for preventing or treating metabolic syndrome
EP3318264A1 (en) 2009-08-24 2018-05-09 Stealth Peptides International, Inc. Methods ans compositions for preventing or treating opthalmic conditions
EP2944317A1 (en) * 2009-10-05 2015-11-18 Cornell University Methods for the prevention or treatment of heart failure
ES2687177T3 (en) * 2010-02-19 2018-10-24 Arizona Board Of Regents, A body corporate of the State of Arizona acting, For and on behalf of Arizona State University Multifunctional radical inhibitors and their use
ES2666404T3 (en) 2010-06-11 2018-05-04 Rhodes Technologies Transition metal catalyzed processes for the preparation and use of N-allyl compounds
AU2011263416B2 (en) 2010-06-11 2014-04-10 Rhodes Technologies Process for N-dealkylation of tertiary amines
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
WO2015184109A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in adult non-human animals
TWI809304B (en) 2014-12-01 2023-07-21 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
PT3242676T (en) 2015-01-07 2023-12-06 TONIX Pharmaceuticals Holding Corp Magnesium-containing oxytocin formulations and methods of use
US20180318279A1 (en) * 2015-10-23 2018-11-08 Rush University Medical Center Topical compositions providing pain relief and methods of use thereof
CN110357808A (en) * 2019-06-13 2019-10-22 上海上药新亚药业有限公司 A kind of crystallization processes of loperamide hydrochloride

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2100711A1 (en) * 1970-06-01 1972-03-24 Janssen Pharmaceutica Nv
US4277605A (en) * 1980-03-07 1981-07-07 Bristol-Myers Company Chemical compounds
EP0127154A2 (en) * 1983-05-26 1984-12-05 The Wellcome Foundation Limited Pharmaceutical peptides, preparation, use and intermediates
EP0582727A1 (en) * 1991-02-13 1994-02-16 LINTEC Corporation Transdermal therapeutic formulation
US5354863A (en) * 1992-01-21 1994-10-11 G. D. Searle & Co. Opioid agonist compounds

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275510A (en) * 1966-09-27 Topical antitussive preparations
US3789072A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
US3714159A (en) * 1971-03-30 1973-01-30 Janssen Pharmaceutica Nv 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides
US3884916A (en) * 1971-03-30 1975-05-20 Janssen Pharmaceutica Nv 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides
US4025652A (en) * 1975-03-31 1977-05-24 William H. Rorer, Inc. Amidinoureas
US4326074A (en) * 1972-09-22 1982-04-20 William H. Rorer, Inc. Amidinoureas
US3950537A (en) * 1973-06-29 1976-04-13 Rohm And Haas Company Gastrointestinally active thioureas
US4060635A (en) * 1975-03-31 1977-11-29 William H. Rorer, Inc. Amidinoureas for treating diarrhea
US3914238A (en) * 1974-01-18 1975-10-21 Janssen Pharmaceutica Nv 4-Aryl-{60 -(1,4-benzodioxan-2-yl)-4-hydroxy-1-piperidineethanols
US3998815A (en) * 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4203920A (en) * 1975-03-31 1980-05-20 William H. Rorer, Inc. Amidinoureas
US4147804A (en) * 1975-03-31 1979-04-03 William H. Rorer, Inc. Amidinourea local anesthetics
US4057549A (en) * 1975-04-16 1977-11-08 G. D. Searle & Co. Triarylpropyl-azabicyclooctanes
US4066654A (en) * 1975-04-16 1978-01-03 G. D. Searle & Co. 1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives
US4072686A (en) * 1975-04-16 1978-02-07 G. D. Searle & Co. 1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols
US3998832A (en) * 1975-04-16 1976-12-21 G. D. Searle & Co. Anti-diarrheal compounds
US4012374A (en) * 1975-09-29 1977-03-15 E. R. Squibb & Sons, Inc. 1-[[4-Phenyl-piperidinyl (or tetrahydropyridinyl)]alkyl]-2,6-piperidinedione and analogs
US3996214A (en) * 1976-02-23 1976-12-07 G. D. Searle & Co. 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto
US4013668A (en) * 1976-03-10 1977-03-22 G. D. Searle & Co. 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds
US4012393A (en) * 1976-03-22 1977-03-15 G. D. Searle & Co. 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5
US4371463A (en) * 1977-02-17 1983-02-01 The United States Of America As Represented By The Department Of Health And Human Services Enzyme-resistant opiate pentapeptides
US4125531A (en) * 1977-04-18 1978-11-14 G. D. Searle & Co. 2-Substituted-1-azabicyclo[2.2.2]octanes
US4069223A (en) * 1977-05-02 1978-01-17 G. D. Searle & Co. 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof
US4116963A (en) * 1977-05-23 1978-09-26 G.D. Searle & Co. 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds
US4218454A (en) * 1977-07-08 1980-08-19 Sri International N-αMethylcyclopropylmethyl derivatives of normorphine and noroodeine, and analgesic compositions and methods employing the normorphine derivatives
US4194045A (en) * 1977-12-27 1980-03-18 G. D. Searle & Co. 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds
US4269843A (en) * 1978-05-24 1981-05-26 Sri International N-Sec-alkyl analogs of norcodeine and normorphine and analgesic compositions and methods employing the normorphine derivatives
US4238390A (en) * 1979-05-09 1980-12-09 Hoffmann-La Roche Inc. Synthesis and biological activity of [D-Thr2, Δ3 Pro5 ]-enkephalinamide
US4384000A (en) * 1980-08-07 1983-05-17 Lanier Earl W Method for treatment of various dermatological conditions
FR2488253A1 (en) * 1980-08-08 1982-02-12 Roques Bernard NEW PEPTIDES AND THEIR THERAPEUTIC APPLICATION
US4328803B1 (en) * 1980-10-20 1994-01-11 Opthalmic Systems, Inc. Opthalmological procedures
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4870084A (en) * 1982-03-16 1989-09-26 Pfizer Inc. Bicyclic benzo fused pyran compounds used for nausea treatment and prevention
US4430327A (en) * 1982-05-18 1984-02-07 Eli Lilly And Company Method for treating pregnant females for pain and anxiety
US4533739A (en) * 1982-10-12 1985-08-06 G. D. Searle & Co. 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity
US4517295A (en) * 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
US4493848A (en) * 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
CH667657A5 (en) 1985-01-07 1988-10-31 Sandoz Ag CARBOCYCLIC AND HETEROCYCLIC CARBONYL METHYLENE AND METHYL PIPERIDINE AND PYRROLIDINE.
US4824853A (en) * 1985-10-11 1989-04-25 Janssen Pharmaceutica N.V. α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea
US4749706A (en) * 1986-03-24 1988-06-07 Sri International Orally active nonaddicting analgesics
US4990521A (en) * 1986-07-03 1991-02-05 Janssen Pharmaceutica 4-(aroylamino)piperidine-butanimide derivatives
US4917896A (en) * 1986-08-15 1990-04-17 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5214080A (en) * 1987-05-15 1993-05-25 Dainippon Ink And Chemicals, Inc. Process for producing nonaqueous dispersion-type resin
US4897260A (en) * 1987-05-22 1990-01-30 The Rockefeller University Compositions that affect suppression of cutaneous delayed hypersensitivity and products including same
DE3874229T2 (en) * 1987-06-16 1993-03-25 British Tech Group USE OF DIOXOPIPERIDINE DERIVATIVES FOR PRODUCING A TOPICAL PREPARATION AS AN ANALGETIC.
US5282851A (en) * 1987-07-07 1994-02-01 Jacob Labarre Jean Intraocular prostheses
US5196405A (en) * 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
US5286751A (en) * 1987-12-24 1994-02-15 Analgesic Associates Sustained/enhanced antipyretic response
HU202195B (en) * 1987-12-31 1991-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing new substituted styrene derivatives and medical compositions comprising such compounds
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5273751A (en) * 1988-03-25 1993-12-28 Seymour Dubroff Composition for preventing clouding of paosterior capsule after extracapsular cataract eye surgery and method of performing cataract surgery
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
US5312899A (en) * 1988-06-30 1994-05-17 Biochem Pharma, Inc. Dermorphin analogs
FR2634376B1 (en) * 1988-07-21 1992-04-17 Farmalyoc NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION
DE3833572A1 (en) * 1988-10-03 1990-04-05 Pfersee Chem Fab STABLE, FINE-PARTIC, AQUEOUS COMPONENT SILICONE CATALYSTS, METHOD FOR THE PRODUCTION AND USE THEREOF
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5025796A (en) * 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5109135A (en) * 1988-12-29 1992-04-28 Sterling Drug Inc. 2- or 3-aminomethyl-4-amino-3,4-dihydro-2H-1,4-benzoxazine intermediates
DE69020752T2 (en) 1989-02-16 1996-03-28 Sankyo Co Peptides that have a renin-inhibiting activity, their production and use.
US5229127A (en) * 1989-03-03 1993-07-20 Mckinzie James W Rapid miosis with control of intraocular pressure using a mixture of a cetylcholine and carbachol derivatives
US5278126A (en) * 1989-03-31 1994-01-11 Ricoh Company, Ltd. Recording process and apparatus and recording medium in the same
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
US5100903A (en) * 1989-05-12 1992-03-31 Anaquest, Inc. N-aryl-n-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5266465A (en) * 1989-06-23 1993-11-30 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
NZ235876A (en) * 1989-11-01 1992-06-25 Mcneil Ppc Inc Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone
US5236947A (en) * 1990-02-28 1993-08-17 Jouveinal S.A. Propanamines, their pharmacological properties and their application as an antidiarrheal
FR2658821B1 (en) * 1990-02-28 1994-09-16 Jouveinal Sa NOVEL PROPANAMINES, THEIR PHARMACOLOGICAL PROPERTIES AND THEIR APPLICATION FOR THERAPEUTIC PURPOSES, ESPECIALLY ANTIDIARRHEUTICS.
DE69122464T2 (en) * 1990-03-30 1997-02-20 Yasunori Morimoto TRANSDERMAL ABSORBABLE AGENT WITH MORPHINE HYDROCHLORIDE
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5366979A (en) * 1990-06-07 1994-11-22 Pharmaco Development Partners Orally active nonaddicting analgesics
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5214148A (en) * 1990-12-18 1993-05-25 Glaxo Inc. Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides
US5116847A (en) * 1991-01-25 1992-05-26 The Procter & Gamble Company Use of loperamide and related compounds for treatment of respiratory disease symptoms
IT1247529B (en) * 1991-04-24 1994-12-17 Poli Ind Chimica Spa PHARMACEUTICAL COMPOSITIONS IN FOAM FORM FOR INTRAVAGINAL, SKIN AND ORAL ADMINISTRATION
FR2676053B1 (en) * 1991-05-03 1993-08-27 Sanofi Elf NOVEL DIALKYLENEPIPERIDINO COMPOUNDS AND THEIR ENANTIOMERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5242944A (en) * 1991-06-20 1993-09-07 Korea Research Institute Of Chemical Technology Phenylacetamide derivatives and pharmaceutical compositions thereof
WO1993002999A1 (en) * 1991-08-10 1993-02-18 Hisamitsu Pharmaceutical Co., Inc. Phenylalkanoic acid derivative, production thereof, and separation of optical isomers thereof
IL99368A (en) 1991-09-02 1996-01-19 Teva Pharma Compositions for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative
NL9102142A (en) * 1991-12-20 1993-07-16 Dagra Pharma Bv Suppositories with delayed release and process for their preparation.
DE69327432T2 (en) * 1992-02-07 2000-05-18 Kaken Pharma Co Ltd MEDICINE FOR Wounds and Hemorrhoid
US5273056A (en) * 1992-06-12 1993-12-28 Alcon Laboratories, Inc. Use of combinations of viscoelastics during surgery
US5645854A (en) * 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
US5460821A (en) * 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB2287404A (en) 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
US5962477A (en) 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5618557A (en) * 1994-11-22 1997-04-08 E.R. Squibb & Sons, Inc. Prophylactic treatment of allergic contact dermatitis
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5888494A (en) 1996-03-12 1999-03-30 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith
US5667773A (en) * 1996-03-12 1997-09-16 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
US5798093A (en) 1997-03-14 1998-08-25 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
US5811078A (en) 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5919473A (en) 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5834480A (en) 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
US5849762A (en) 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2100711A1 (en) * 1970-06-01 1972-03-24 Janssen Pharmaceutica Nv
US4277605A (en) * 1980-03-07 1981-07-07 Bristol-Myers Company Chemical compounds
EP0127154A2 (en) * 1983-05-26 1984-12-05 The Wellcome Foundation Limited Pharmaceutical peptides, preparation, use and intermediates
EP0582727A1 (en) * 1991-02-13 1994-02-16 LINTEC Corporation Transdermal therapeutic formulation
US5354863A (en) * 1992-01-21 1994-10-11 G. D. Searle & Co. Opioid agonist compounds

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ADELSTEIN ET AL.: "3,3-Diphenyl-3-(2-alkyl-1,3,4-oxadiazol-5-yl)propylcycloalkylamines, a Novel Series of Antidiarrheal Agents.", J. MED. CHEM., vol. 19, no. 10, 1976, pages 1221 - 1225, XP002029507 *
GOODMAN ET AL.: "The pharmacological basis of Therapeutics", 1985, MACMILLAN, NEW YORK, XP002029508, 131620 *
GOTTSCHLICH, R. ET AL.: "The Peripherally acting kappa-opiate agonist EMD 61753 and analogues: Opioid activity versus peripheral selectivity.", DRUGS EXPTL. CLIN. RES., vol. 21, no. 5, 1995, pages 171 - 174, XP000609171 *
LEVINE, J.D.; TAIWO, Y.O.: "Involvement of the mu-Opiate receptor in peripheral analgesia.", NEUROSCIENCE, vol. 32, no. 3, 1989, pages 571 - 576, XP000609169 *
MACKERER ET AL.: "Antidiarrheal and central nervous system activities of SC-27166 (2-[3-5-methyl-1,3,4-oxadiazol-2-yl)-3,3-diphenylpropyl]-2-azabicyclo[2.2.2]octane), a new antidiarrheal agent, resulting from binding to opiate receptor sites of brain and myenteric plexus", J. PHARMACOL. EXP. THER., vol. 203, no. 3, 1977, pages 527 - 538, XP000670177 *
MACKERER ET AL.: "Loperamide binding to opiate receptor sites of brain and myenteric plexus.", J. PHARMACOL. EXP. THER., vol. 199, 1976, pages 131 - 140, XP000670263 *
MACKERER ET AL.: "Review of the Involvement of Opiate Receptors in Producing the Central and Peripheral Effects Caused by two New Antidiarrheal Drugs, Loperamide and SC-27166.", J. AM. COLL. TOXICOL., vol. 3, 1984, pages 81 - 91, XP000670159 *
MEGENS ET AL.: "Is In Vivo Dissociation Between the Antipropulsive and Antidiarrheal Porperties of Opioids in Rats Related to Gut Selectivity?", ARCH. INT. PHARMACODYN. THER., vol. 298, 1989, pages 220 - 229, XP000670160 *
MEGENS ET AL.: "Normalization of small intestinal propulsion with loperamide-like antidiarrheals in rats.", EUR. J. PHARMACOL., vol. 178, no. 3, 1990, pages 357 - 364, XP000670152 *
MOLINA, N. ET. AL: "The peripheral analgesic effects of Morphine, Codeine, Pentazocine and D-Propoxyphene.", BRAZILIAN J. MED. BIOL. RES., vol. 16, 1983, pages 345 - 352, XP000609164 *
NIEMEGEERS ET AL.: "Dissociation between Opiate-Like and Antidiarrheal Activities of Antidiarrheal Drugs", J. PHARMACOL. EXP. THER., vol. 210, no. 3, 1979, pages 327 - 333, XP000670158 *
SMITH, T.W. ET AL.: "Peripheral antinociceptive effects of N-Methyl Morphine", LIFE SCIENCES, vol. 31, 1982, pages 1205 - 1208, XP000611242 *
STOKBROEKX ET AL.: "Synthetic Antidiarrheal Agents. 2,2-diphenyl-4-(4'-aryl-4'hydroxypiperidino)butyramides", J. MED. CHEM., vol. 16, no. 7, 1973, P0C038, pages 782 - 786, XP000567748 *
VAN DER KOOY, D.: "Hyperalgesic Functions of Peripheral Opiate Receptors", ANN. N. Y. ACAD. SCI., vol. 467, 1986, pages 154 - 168, XP000609166 *

Also Published As

Publication number Publication date
CA2229814C (en) 2001-12-04
US5994372A (en) 1999-11-30
US5849761A (en) 1998-12-15
JP3553083B2 (en) 2004-08-11
WO1997009973A2 (en) 1997-03-20
JPH11512438A (en) 1999-10-26
CA2356097A1 (en) 1997-03-20
NO980700D0 (en) 1998-02-19
BR9610345A (en) 1999-06-01
AU727982C (en) 2001-10-18
AU7071096A (en) 1997-04-01
KR19990044182A (en) 1999-06-25
JP2002069004A (en) 2002-03-08
US6576650B1 (en) 2003-06-10
MX9801514A (en) 1998-10-31
AU727982B2 (en) 2001-01-04
EP0852494A2 (en) 1998-07-15
US6166039A (en) 2000-12-26
NO980700L (en) 1998-05-12
CA2229814A1 (en) 1997-03-20

Similar Documents

Publication Publication Date Title
WO1997009973A3 (en) Peripherally active anti-hyperalgesic opiates
CA2260943A1 (en) Formulation of 5-ht agonists
NZ319531A (en) An analgesic synergistic composition containing a sub-analgesic dose of a mu opioid agonist and a kappa-2 opiod agonist
YU59098A (en) Substituted spiro-piperidine derivatives
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
SI0725779T1 (en)
AU7085996A (en) Therapeutic preparation for the transdermal application of active substances through the skin
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
AU3419995A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
IL133600A0 (en) Compositions and methods for reducing respiratory depression and attendant side effects of mu opiod compounds
DE60113290D1 (en) TREATMENT OF SEXUAL FUNCTIONAL TROUBLESHOOTING WITH BOMBESIN RECEPTOR ANTAGONISTS
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
CA2176298A1 (en) A single high dose fluoroquinolone treatment
AU9547598A (en) Analgesic compositions
CA2164842A1 (en) Use of isovaleramide as a mild anxiolytic and mild sedative agent
ES2058596T3 (en) USE OF L-CARNITINE DERIVATIVES IN THE THERAPEUTIC TREATMENT OF DEGENERATIVE ALTERATIONS OF THE NERVOUS SYSTEM.
MXPA05012738A (en) (1s,5s)-3-(5, 6-dichloro-3 -pyridinyl)-3, 6-diazabicyclo [3.2.0] heptane is an effective analgesic agent.
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
AU6846300A (en) Use of cyamemazine for cold turkey benzodiazepine treatment
CA2233677A1 (en) A novel combination of a .beta.-receptor blocker and an opioid
CA2452432A1 (en) Active ingredient combination for the pharmacological therapy of nicotine dependence
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
HK1026608A1 (en) Composition comprising ketanserin and l-carnitine for the treatment of crps
CA2235617A1 (en) Therapeutic preparation for the transdermal administration of active substances

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2229814

Country of ref document: CA

Ref country code: CA

Ref document number: 2229814

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/001514

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019980701417

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 512136

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996931567

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996931567

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980701417

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980701417

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996931567

Country of ref document: EP